Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M27.0Revenue (TTM) $M--Net Margin (%)--Altman Z-Score4.0
Enterprise Value $M0.7EPS (TTM) $-1.4Operating Margin %--Piotroski F-Score3
P/E(ttm)--Beneish M-Score-3.0Pre-tax Margin (%)--Higher ROA y-yY
Price/Book0.910-y EBITDA Growth Rate %-52.1Quick Ratio15.8Cash flow > EarningsY
Price/Sales--5-y EBITDA Growth Rate %-46.2Current Ratio15.8Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-34.4Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-35.9Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M9.1ROIC % (ttm)-965.8Gross Margin Increase y-yN

Gurus Latest Trades with ABIO

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ABIOFirst Eagle Investment 2010-03-31 Sold Out -0.01%$110.88 - $345.24
($133.7)
$ 2.98-98%Sold Out0
ABIOFirst Eagle Investment 2009-12-31 Reduce-0.01%$94.5 - $181.44
($126.59)
$ 2.98-98%Reduce -27.96%9,817
ABIOFirst Eagle Investment 2009-09-30 Add0.01%$95.76 - $184.8
($146.13)
$ 2.98-98%Add 62.38%13,627
ABIOFirst Eagle Investment 2009-06-30 Add$108.36 - $564.9
($288.19)
$ 2.98-99%Add 24.34%8,392
ABIOFirst Eagle Investment 2009-03-31 Buy 0.02%$163.8 - $275.86
($219.26)
$ 2.98-99%New holding6,749
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ABIO is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


ABIO: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BRISTOW MICHAEL RSee Remarks 2016-04-05Sell724$3.52-15.34view
Ozeroff Christopher DavidS.V.P., General Counsel 2016-04-05Sell366$3.52-15.34view
Keuer Thomas ACOO 2016-04-05Sell384$3.52-15.34view
Selby Brian L.VP, Finance 2016-04-04Sell1,114$3.52-15.34view
Keuer Thomas ACOO 2016-03-01Sell457$3.53-15.58view
Ozeroff Christopher DavidS.V.P., General Counsel 2016-03-01Sell458$3.51-15.1view
BRISTOW MICHAEL RSee Remarks 2016-03-01Sell752$3.5-14.86view
Selby Brian L.VP, Finance 2016-02-29Sell160$3.46-13.87view
Keuer Thomas ACOO 2015-10-16Sell496$5.14-42.02view
Selby Brian L.VP, Finance 2015-09-18Sell476$6.23-52.17view

Quarterly/Annual Reports about ABIO:

News about ABIO:

Articles On GuruFocus.com
ARCA BIOPHARMA, INC. Reports Operating Results (10-Q) Nov 15 2010 
ARCA BIOPHARMA, INC. Reports Operating Results (10-Q) Aug 10 2010 
ARCA BIOPHARMA, INC. Reports Operating Results (10-Q) May 10 2010 
ARCA BIOPHARMA, INC. Reports Operating Results (10-Q) Nov 16 2009 
ARCA BIOPHARMA, INC. Reports Operating Results (10-Q) Aug 10 2009 
ARCA biopharma Inc. Reports Operating Results (10-Q) May 15 2009 
ARCA biopharma Inc. Reports Operating Results (10-Q) Feb 07 2009 

More From Other Websites
ARCA BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 18 2016
ARCA BIOPHARMA, INC. Financials Aug 18 2016
ARCA biopharma Announces 100th Patient Randomized into the Genetic-AF Phase 2B/3 Clinical Trial Aug 18 2016
ARCA biopharma Announces 100th Patient Randomized into the GENETIC-AF Phase 2B/3 Clinical Trial Aug 18 2016
ARCA biopharma Announces Second Quarter 2016 Financial Results and Provides Business Update Aug 09 2016
ARCA BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 09 2016
ARCA biopharma Announces Second Quarter 2016 Financial Results and Provides Business Update Aug 09 2016
Albioma :ABIO-FR: Earnings Analysis: For the six months ended June 30, 2016 : August 3, 2016 Aug 03 2016
ARCA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of... Jun 13 2016
ARCA biopharma Announces First Quarter 2016 Financial Results and Provides Business Update May 11 2016
ARCA BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 11 2016
ARCA BIOPHARMA, INC. Files SEC form 10-Q, Quarterly Report May 11 2016
ARCA biopharma Announces First Quarter 2016 Financial Results and Provides Business Update May 11 2016
ARCA BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 18 2016
ARCA biopharma Announces 75th Patient Enrolled in Genetic-AF Phase 2B/3 Clinical Trial Apr 18 2016
ARCA biopharma Announces 75th Patient Enrolled in GENETIC-AF Phase 2B/3 Clinical Trial Apr 18 2016
ARCA BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Mar 17 2016
ARCA biopharma Announces Fiscal Year 2015 Financial Results and Provides Business Update Mar 17 2016
ARCA BIOPHARMA, INC. Files SEC form 10-K, Annual Report Mar 17 2016
Bearish case for Valeant Mar 17 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)